I am interested in seeing how much (if any) myeloma patient outcomes differ based on which country they live in. If any one has seen any studies with regard to this topic I would be interested in seeing them. One was recently published that showed little difference in 5 year overall survival between Germany and the United States.
"Multiple myeloma is a chronic, incurable but highly treatable neoplasm. Recent population-based studies have shown improvements in survival for patients diagnosed in the early 21st century. Here, we examine trends in survival for patients diagnosed with multiple myeloma in Germany and the United States (US) between 2002 and 2010. Data were extracted from 11 population-based cancer registries in Germany and from the Surveillance, Epidemiology and End Results database in the US. Myeloma patients aged 15-74 years with diagnosis and follow-up between 1997 and 2010 from Germany and the US were included. Period analysis was employed to assess trends in 5-year relative survival in Germany and the US between 2002-04 and 2008-10. Age-adjusted 5-year relative survival increased from 47·3% to 53·8% in Germany and from 39·8% to 53·2% in the US between 2002-04 and 2008-10. There was a strong age gradient with lower survival among older patients, which persisted over time and was more pronounced in Germany than the US. Five-year relative survival estimates for patients diagnosed with multiple myeloma below 75 years of age steadily increased throughout the first decade of the 21st century and reached levels above 50% in both Germany and the US, probably reflecting the increased use of newer agents in myeloma treatment."
http://www.ncbi.nlm.nih.gov/pubmed/26123295
Forums
5 posts
• Page 1 of 1
Re: Patient Outcomes By Country/Region
Mark 11
In England Recent Office of National Statistics gives predicted age standardised 5 year survival figure of people diagnosed in 2013 as around 51% for women and 53% for men.The view is myeloma survival rates have been improving ahead of other common cancers.
http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-survival-in-england--adults-diagnosed/2008-to-2012--followed-up-to-2013/stb-cancer-survival.html
Edna
In England Recent Office of National Statistics gives predicted age standardised 5 year survival figure of people diagnosed in 2013 as around 51% for women and 53% for men.The view is myeloma survival rates have been improving ahead of other common cancers.
http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-survival-in-england--adults-diagnosed/2008-to-2012--followed-up-to-2013/stb-cancer-survival.html
Edna
Re: Patient Outcomes By Country/Region
Hi Mark and Edna,
In Canada, according to 2010 data from the Canadian Cancer Society, the relative five-year survival rate is only 43%. It is broken into stages at diagnosis though. Stage 1 at 62 months average survival, 44 months at Stage 2, and 29 months at Stage 3. There is more info about myeloma on their site, and of course a person is not a statistic. Those are average survivals, but still daunting. As treatments and drugs used to fight myeloma become available here, one hopes that the statistics will improve!
Actually a five-year span ending in 2010 would be from 2005. In 2005, neither Velcade or Revlimid were approved and funded here, let alone Pomalyst, which was only funded in 2015, for 8 provinces now.
There were probably clinical trials available in 2005, but as has been discussed on the Beacon, not everyone can avail themselves of those. So now, the five-year relative survival may well be above 43%.
Does anyone else have these Canadian stats from later than 2010?
In Canada, according to 2010 data from the Canadian Cancer Society, the relative five-year survival rate is only 43%. It is broken into stages at diagnosis though. Stage 1 at 62 months average survival, 44 months at Stage 2, and 29 months at Stage 3. There is more info about myeloma on their site, and of course a person is not a statistic. Those are average survivals, but still daunting. As treatments and drugs used to fight myeloma become available here, one hopes that the statistics will improve!
Actually a five-year span ending in 2010 would be from 2005. In 2005, neither Velcade or Revlimid were approved and funded here, let alone Pomalyst, which was only funded in 2015, for 8 provinces now.
There were probably clinical trials available in 2005, but as has been discussed on the Beacon, not everyone can avail themselves of those. So now, the five-year relative survival may well be above 43%.
Does anyone else have these Canadian stats from later than 2010?
-
Nancy Shamanna - Name: Nancy Shamanna
- Who do you know with myeloma?: Self and others too
- When were you/they diagnosed?: July 2009
Re: Patient Outcomes By Country/Region
Here's the stats from Scotland: For Period 2007 to 2011, 5 year survival is 51.9% for men and 43.0% for women, and 47.7% for all. Big difference between men and women, is that usual?
Summary statistics for multiple myelomas:
Scotland Males Females Persons
Rank - incidence (2013) 15 19 18
Rank - mortality (2013) 15 16 16
Percentage frequency of all cancers - incidence (2013) 1.5% 1.0% 1.2%
Percentage frequency of all cancers - mortality (2013) 1.5% 1.4% 1.4%
Number of new cases diagnosed in 2013 220 162 382
Number of deaths recorded in 2013 118 105 223
Change in incidence from 2003 to 2013 +3.4% -3.5% +0.7%
Change in mortality from 2003 to 2013 -4.9% -15.5% -9.3%
1 year relative survival for patients diagnosed between 2007 and 2011 76.8% 74.2% 75.5%
5 year relative survival for patients diagnosed between 2007 and 2011 51.9% 43.0% 47.7%
Notes:
1. Survival figures are not age standardised.
2. Change in incidence and mortality is estimated by Poisson regression.
Ref: http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Multiple-Myeloma/
Laura
Summary statistics for multiple myelomas:
Scotland Males Females Persons
Rank - incidence (2013) 15 19 18
Rank - mortality (2013) 15 16 16
Percentage frequency of all cancers - incidence (2013) 1.5% 1.0% 1.2%
Percentage frequency of all cancers - mortality (2013) 1.5% 1.4% 1.4%
Number of new cases diagnosed in 2013 220 162 382
Number of deaths recorded in 2013 118 105 223
Change in incidence from 2003 to 2013 +3.4% -3.5% +0.7%
Change in mortality from 2003 to 2013 -4.9% -15.5% -9.3%
1 year relative survival for patients diagnosed between 2007 and 2011 76.8% 74.2% 75.5%
5 year relative survival for patients diagnosed between 2007 and 2011 51.9% 43.0% 47.7%
Notes:
1. Survival figures are not age standardised.
2. Change in incidence and mortality is estimated by Poisson regression.
Ref: http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Multiple-Myeloma/
Laura
-
LauraScot - Name: Laura
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: 2013
- Age at diagnosis: 47
Re: Patient Outcomes By Country/Region
Thanks everyone for the responses. I am surprised Canada looks to be a bit lower than the others. I thought they would all be "in the same ballpark".
-
Mark11
5 posts
• Page 1 of 1